By vgreene, 25 April, 2020 Proposed mechanism: reduces inflammatory response by inhibiting dihydroorotate dehydrogenase; in vitro effects against SARS-CoV-2
By vgreene, 25 April, 2020 Proposed mechanism: reduces inflammatory response by inhibiting IL-1 receptors
By vgreene, 25 April, 2020 FDA MedWatch: Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems; see FDA alert
By vgreene, 25 April, 2020 Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients With Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial; access Med article
By vgreene, 25 April, 2020 Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients With Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial; access Med article
By vgreene, 25 April, 2020 FDA MedWatch: Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems; see FDA alert